Adrenocortical Carcinoma Treatment Market Research Report Information By Type (Localized Adrenocortical Carcinoma, Metastatic Adrenocortical Carcinoma), Therapy (Radiation Therapy and Others), End-User (Hospitals and Clinics and Others) -Forecast till 2032

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Adrenocortical Carcinoma Treatment Market, by Type

6.1 Introduction

6.2 Localized Adrenocortical Carcinoma

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

6.3 Metastatic Adrenocortical Carcinoma

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 7. Global Adrenocortical Carcinoma Treatment Market, by Therapy

7.1 Introduction

7.2 Surgery

7.2.1 Laparoscopic surgery

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.2.2 Open surgery

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.3 Chemotherapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.4 Targeted Therapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.5 Radiation Therapy

7.5.1 External beam radiation therapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.5.2 Brachytherapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.6 Adjuvant Therapy

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

7.7 Others

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 8. Global Adrenocortical Carcinoma Treatment Market, by End-User

8.1 Introduction

8.2 Hospitals and Clinics

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.3 Ambulatory Surgical Centers

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

8.4 Cancer Research Institutes

Market Estimates & Forecast, by Region, 2020–2027

Market Estimates & Forecast, by Country, 2020–2027

Chapter 9. Global Adrenocortical Carcinoma Treatment, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

Chapter 11. Company Profiles

11.1 Arqule

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials Overview

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 Pfizer Ltd.

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 EnGeneIC Ltd

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Exelixis, Inc.

11.4.1 Company Overview

11.4.2 Product Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Millendo Therapeutics, Inc.

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Merck & Co.

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Orphagen Pharmaceuticals, Inc.

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financial Overview

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 HRA Pharma

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Bristol-Myers Squibb Company

11.9.1 Overview

11.9.2 Product Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 General Electric Company

11.10.1 Overview

11.10.2 Product Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 WG Critical Care, LLC

11.11.1 Overview

11.11.2 Product Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.12 Mylan N.V.

11.12.1 Overview

11.12.2 Product Overview

11.12.3 Financials

11.12.4 Key Developments

11.12.5 SWOT Analysis

11.13 Fresenius Kabi AG

11.13.1 Overview

11.13.2 Product Overview

11.13.3 Financials

11.13.4 Key Developments

11.13.5 SWOT Analysis

11.14 SINOVISION Technologies (Beijing)CO., Ltd.

11.14.1 Overview

11.14.2 Product Overview

11.14.3 Financials

11.14.4 Key Developments

11.14.5 SWOT Analysis

11.15 Hitachi, Ltd.

11.15.1 Overview

11.15.2 Product Overview

11.15.3 Financials

11.15.4 Key Developments

11.15.5 SWOT Analysis

11.16 NeuroLogica Corp.

11.16.1 Overview

11.16.2 Product Overview

11.16.3 Financials

11.16.4 Key Developments

11.16.5 SWOT Analysis

11.17 Digirad Corporation

11.17.1 Overview

11.17.2 Product Overview

11.17.3 Financials

11.17.4 Key Developments

11.17.5 SWOT Analysis

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s Viewpoint

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Predictions for the Adrenocortical Carcinoma Treatment Industry

Chapter 13. Appendix

LIST OF TABLES

Table 1 Global Adrenocortical Carcinoma Treatment Market Synopsis, 2020–2027

Table 2 Global Adrenocortical Carcinoma Treatment Market Estimates and Forecast, 2020–2027 (USD Million)

Table 3 Global Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)

Table 4 Global Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)

Table 5 Global Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 6 Global Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027(USD Million)

Table 7 North America: Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)

Table 8 North America: Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)

Table 9 North America: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 10 North America: Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027 (USD Million)

Table 11 US: Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)

Table 12 US: Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)

Table 13 US: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 14 US: Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027 (USD Million)

Table 15 Canada: Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)

Table 16 Canada: Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)

Table 17 Canada: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 18 Canada: Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027 (USD Million)

Table 19 South America: Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)

Table 20 South America: Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)

Table 21 South America: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 22 South America: Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027 (USD Million)

Table 23 Europe: Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)

Table 24 Europe: Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)

Table 25 Europe: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 26 Europe: Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027 (USD Million)

Table 27 Western Europe: Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)

Table 28 Western Europe: Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)

Table 29 Western Europe: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 30 Western Europe: Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027 (USD Million)

Table 31 Eastern Europe: Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)

Table 32 Eastern Europe: Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)

Table 33 Eastern Europe: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 33 Eastern Europe: Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027 (USD Million)

Table 33 Asia-Pacific: Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)

Table 33 Asia-Pacific: Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)

Table 34 Asia-Pacific: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 35 Asia-Pacific: Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027 (USD Million)

Table 36 Middle East & Africa: Adrenocortical Carcinoma Treatment Market, by Type, 2020–2027 (USD Million)

Table 37 Middle East & Africa: Adrenocortical Carcinoma Treatment Market, by Therapy, 2020–2027 (USD Million)

Table 38 Middle East & Africa: Adrenocortical Carcinoma Treatment Market, by End-User, 2020–2027 (USD Million)

Table 39 Middle East & Africa: Adrenocortical Carcinoma Treatment Market, by Region, 2020–2027 (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Adrenocortical Carcinoma Treatment Market

Figure 3 Segmentation Market Dynamics for Global Adrenocortical Carcinoma Treatment Market

Figure 4 Global Adrenocortical Carcinoma Treatment Market Share, by Type, 2020 (%)

Figure 5 Global Adrenocortical Carcinoma Treatment Market Share, by Therapy, 2020 (%)

Figure 6 Global Adrenocortical Carcinoma Treatment Market Share, by End-User, 2020 (%)

Figure 7 Global Adrenocortical Carcinoma Treatment Market Share, by Region, 2020 (%)

Figure 8 North America: Adrenocortical Carcinoma Treatment Market Share, by Country, 2020 (%)

Figure 9 Europe: Adrenocortical Carcinoma Treatment Market Share, by Country, 2020 (%)

Figure 10 Asia-Pacific: Adrenocortical Carcinoma Treatment Market Share, by Country, 2020 (%)

Figure 11 Middle East & Africa: Adrenocortical Carcinoma Treatment Market Share, by Country, 2020 (%)

Figure 12 Global Adrenocortical Carcinoma Treatment Market: Company Share Analysis, 2020 (%)

Figure 13 Arqule: Key Financials

Figure 14 Arqule: Segmental Revenue

Figure 15 Arqule: Geographical Revenue

Figure 16 Pfizer Ltd.: Key Financials

Figure 17 Pfizer Ltd.: Segmental Revenue

Figure 18 Pfizer Ltd.: Geographical Revenue

Figure 19 EnGeneIC Ltd: Key Financials

Figure 20 EnGeneIC Ltd: Segmental Revenue

Figure 21 EnGeneIC Ltd: Geographical Revenue

Figure 22 Exelixis, Inc.: Key Financials

Figure 23 Exelixis, Inc.: Segmental Revenue

Figure 24 Exelixis, Inc.: Geographical Revenue

Figure 25 Millendo Therapeutics, Inc.: Key Financials

Figure 26 Millendo Therapeutics, Inc.: Segmental Revenue

Figure 27 Millendo Therapeutics, Inc.: Geographical Revenue

Figure 28 Merck & Co.: Key Financials

Figure 29 Merck & Co.: Segmental Revenue

Figure 30 Merck & Co.: Geographical Revenue

Figure 31 Orphagen Pharmaceuticals, Inc.: Key Financials

Figure 32 Orphagen Pharmaceuticals, Inc.: Segmental Revenue

Figure 33 Orphagen Pharmaceuticals, Inc.: Geographical Revenue

Figure 34 HRA Pharma: Key Financials

Figure 35 HRA Pharma: Segmental Revenue

Figure 36 HRA Pharma: Geographical Revenue

Figure 37 Bristol-Myers Squibb Company: Key Financials

Figure 38 Bristol-Myers Squibb Company: Segmental Revenue

Figure 39 Bristol-Myers Squibb Company: Geographical Revenue

Figure 40 General Electric Company: Key Financials

Figure 41 General Electric Company: Segmental Revenue

Figure 42 General Electric Company: Geographical Revenue

Figure 43 WG Critical Care, LLC: Key Financials

Figure 44 WG Critical Care, LLC: Segmental Revenue

Figure 45 WG Critical Care, LLC: Geographical Revenue

Figure 46 Mylan N.V.: Key Financials

Figure 47 Mylan N.V.: Segmental Revenue

Figure 48 Mylan N.V.: Geographical Revenue

Figure 49 Fresenius Kabi AG: Key Financials

Figure 50 Fresenius Kabi AG: Segmental Revenue

Figure 51 Fresenius Kabi AG: Geographical Revenue

Figure 52 SINOVISION Technologies (Beijing)CO.,Ltd.: Key Financials

Figure 53 SINOVISION Technologies (Beijing)CO.,Ltd.: Segmental Revenue

Figure 54 SINOVISION Technologies (Beijing)CO.,Ltd.: Geographical Revenue

Figure 55 Hitachi, Ltd.: Key Financials

Figure 56 Hitachi, Ltd.: Segmental Revenue

Figure 57 Hitachi, Ltd.: Geographical Revenue

Figure 58 NeuroLogica Corp.: Key Financials

Figure 59 NeuroLogica Corp.: Segmental Revenue

Figure 60 NeuroLogica Corp.: Geographical Revenue

Figure 61 Digirad Corporation: Key Financials

Figure 62 Digirad Corporation: Segmental Revenue

Figure 63 Digirad Corporation: Geographical Revenue